Ovarian cancer is a leading cause of cancer mortality in women. The aim of this study was to elucidate whether whey acidic protein (WAP) genes on chromosome 20q13.12, a region frequently amplified in this cancer, are expressed in serous carcinoma, the most common form of the disease. Herein, we report that a trio of WAP genes (HE4, SLPI, and Elafin) is overexpressed and secreted by serous ovarian carcinomas. To our knowledge, this is the first report linking Elafin to ovarian cancer. Fluorescence in situ hybridization analysis of primary tumors demonstrates genomic gains of the Elafin locus in a majority of cases. In addition, a combination of peptidomimetics, RNA interference, and chromatin immunoprecipitation experiments shows that Elafin expression can be transcriptionally upregulated by inflammatory cytokines through activation of the nuclear factor κB pathway. Importantly, using a clinically annotated tissue microarray composed of late-stage, high-grade serous ovarian carcinomas, we show that Elafin expression correlates with poor overall survival. These results, combined with our observation that Elafin is secreted by ovarian tumors and is minimally expressed in normal tissues, suggest that Elafin may serve as a determinant of poor survival in this disease.
Introduction
Ovarian cancer is a major cause of cancer-related mortality in women worldwide [1, 2] . Fortuitous detection of early-stage organ-confined disease is associated with an excellent prognosis and a 5-year survival rate greater than 90% [3] . However, because of a lack of effective screening methods, conditions of most patients are diagnosed at an advanced stage when the opportunity for a surgical cure is drastically reduced. Furthermore, whereas most patients with advanced disease initially respond to standard chemotherapeutic regimens, the majority ultimately relapses with chemoresistant disease [3] . Therefore, there is a pressing need to develop new methods for early detection and prognostication. CA125 is an ovarian cancer serum biomarker clinically approved for monitoring response to treatment and detection of disease recurrence after definitive therapy [4] . However, its potential role in the early detection of ovarian cancer is controversial, in part because randomized screening trials of asymptomatic women with ovarian cancer mortality as an end point have yet to be completed [5] .
Previous studies using comparative genomic hybridization and in silico chromosomal clustering reported that human chromosome 20q12-13.2 is consistently amplified in ovarian carcinomas and harbors genes that may play causal roles in the pathogenesis of the disease [6] [7] [8] [9] [10] . This region contains a cluster of 14 genes with homology to whey acidic protein (WAP) [11, 12] . Among these genes is HE4 [11] . On the basis of studies from our laboratory and others showing that HE4 is secreted by ovarian carcinomas and circulates in the blood stream of patients with the disease [13, 14] , we investigated whether other members of the WAP gene cluster are also overexpressed in this setting. Herein, we report that a trio of WAP genes, composed of HE4, SLPI, and Elafin, is overexpressed and secreted by ovarian carcinomas. Of the three, Elafin is the only one not previously reported to be associated with ovarian cancer [13] [14] [15] [16] [17] [18] . Elafin is a serine proteinase inhibitor involved in inflammation and wound healing [19] . Our studies show that Elafin overexpression is associated with poor overall survival and is due, in part, to gains of the genomic locus and the ability to activate the nuclear factor κB (NF-κB) pathway in ovarian cancer cells.
Materials and Methods

Cell Lines
Twenty established cell lines were used to evaluate the messenger RNA and protein expression of the WAP genes. They included OVCA420, OVCA429, OVCAR-3, OV-90, SKOV3, CaOV3, OVCAR-5, OVCAR-8, IGROV1, TOV112D, TOV21G, ES2, HEYA8, MCF7, T47D, HCT116, HCT115, U2OS, 293, and IMR90. A majority of the lines were obtained from American Type Culture Collection (ATCC, Manassas, VA) and propagated in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen) at 37°C in a 5% CO 2 -containing atmosphere. Two cell lines, OV-90 and OVCAR-3, were propagated in 1:1 MCDB105 and Media 199 (Sigma-Aldrich, St Louis, MO) with 15% FBS, whereas CaOV3, ES2, IGROV1, HCT116, HCT115, 293, MCF7, and IMR90 were propagated in Dulbecco's modification of Eagle medium (Cellgro, Herndon, VA) with 10% FBS. Expression of the different WAP genes, including Elafin, in these lines was compared with that of telomerase-immortalized ovarian surface epithelial (IOSE) as previously described [13] . The term human ovarian surface epithelium (HOSE) is used inter-changeably with IOSE.
Reverse Transcription-Polymerase Chain Reaction and Quantitative Polymerase Chain Reaction RNA was purified as previously described [8] . Complementary DNA (cDNA) was synthesized from each cell line using 1 mg of RNA, extracted from the cell lines described above, using the iScript cDNA synthesis Kit (Bio-Rad, Hercules, CA) following the manufacturer's recommendations. Epididymis cDNA was synthesized from RNA obtained from BD Biosciences, Clontech (Palo Alto, CA). Polymerase chain reaction (PCR) primers are listed in Table W1 . PCR products were identified on a 2.5% Tris-acctate-EDTA agarose gel. Quantitative amplification data were generated from 10 ng of cDNA on Bio-Rad's iCycler in conjunction with IQ SYBR Green (Bio-Rad, Hercules, CA). However, when confirming Elafin expression in microdissected late-stage high-grade serous tumors (n = 20) and normal OSE (n = 10), 50 ng of amplified RNA was used.
Recombinant Protein and Antibody Production
The full-length Elafin transcript was ligated into the pGEX-2T vector (GE Healthcare Bio-Sciences Corp, Piscataway, NJ). The modified vector was transformed into Escherichia coli Top10 (Invitrogen) where it was amplified. The insert-containing vector was sequenced to confirm positive selection. Induction and purification of recombinant protein were done as previously described [13] . Elafin-specific antibodies were raised by immunizing New Zealand White rabbits with glutathione S-transferase (GST) fusion protein composed of full-length Elafin and GST. Affinity-purified antibodies were generated as previously described [13] . Elafin monoclonal antibodies were purchased from Cell Sciences (Canton, MA). Recombinant untagged Elafin was purchased from R&D Systems (Minneapolis, MN).
Affymetrix GeneChip Amplification, Hybridization, and Image Acquisition
Total RNA quality for each tumor and normal OSE specimen was checked by BioAnalyzer (Agilent, Palo Alto, CA) before further manipulation. Two rounds of amplification were completed according to the Affymetrix Two-Cycle Amplification protocol using 25 ng of total RNA for tumor and normal OSE as previously described [20] . A 15-μg aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA). Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).
Microarray Analysis
The Robust Multichip Analysis (RMA) algorithm was applied to the normal OSE and tumor array data. Biometric Research Branch (BRB) ArrayTools version 3.2.2 software developed by Dr. Richard Simon and Amy Peng Lam of the Biometrics Research Branch of the National Cancer Institute was used to filter and complete the statistical analysis. Only those probe sets present in greater than 50% of the arrays and displaying a variance in the top 50th percentile were evaluated.
Differentially expressed genes were identified for tumor and OSE specimens using a multivariate permutation t-test (P < .05). A total of 2000 permutations were completed to identify a list of probe sets containing fewer than 5% false-positives at a confidence of 90%. A random-variance model was selected to permit information sharing among probe sets.
Immunoblot Analysis
Western blots were done as previously described [13] . All blots were developed using HRP Oxidizing and Luminol Solutions (Boston Bioproducts, Worcester, MA) and analyzed on the FlourChem HD2 imaging system (Alpha Innotech, San Leandro, CA).
RNA Interference
Knockdown of NF-κB activity was achieved by targeting the p65 subunit with an small interfering RNA (siRNA) SMARTpool containing four individual siRNA against p65 (Upstate/Millipore, Charlottesville, VA). The SMARTpool sequences are 5′-GAUGAGAUCUUCCU-ACUGU, 5′-GGAUUGAGGAGAAACGUAA, 5′-CUCAAGAU-CUGCCGAGUGA, and 5′-GGCUAUAACUCGCCUAGUG and are collectively labeled as siRNA p65 (1) . A second independent siRNA against p65 (5′-GCUGAAGUGCAUCCAAAGGTT) was used as a control for off-target effects (Cell Signaling, Danvers, MA) and was labeled as siRNA p65 (2) . An NF-κB p65-specific antibody (sc-372; Santa Cruz Technologies, Santa Cruz, CA) was used to analyze total cell extracts from cells treated with the p65 SMARTpool versus control siRNA. Equal protein loading was confirmed by immunostaining of glyceraldehyde-3-phosphate dehydrogenase (Abcam, Cambridge, MA).
Tumor-Normal Northern Blot Analysis
Membranes loaded with RNA from matched tumor and normal tissue samples were purchased from Clontech (Cancer Profiling Arrays I and II; Mountain View, CA). An Elafin-specific probe was generated by random priming of Elafin cDNA using TaKaRa Ladderman Labeling Kit (Takara Bio, Inc, Madison, WI) according to the manufacturer's instructions. Hybridization of the membranes was carried out as described in the Cancer Profiling Array manual. The labeled membranes were placed in a phosphor screen cassette for 14 days before it was scanned on a Molecular Dynamics' STORM860 system (GE Healthcare BioSciences Corp). The phosphoimage was analyzed using ImageQuant v1.2 (Molecular Dynamics; GE Healthcare Bio-Sciences Corp).
Chromatin Immunoprecipitation
The nucleotide sequence located 1 kb upstream of the start codon of Elafin was analyzed using a combination of algorithms that can predict potential transcription factor binding sites (TESS http://www.cbil. upenn.edu/cgi-bin/tess/tess and AliBaba http://darwin.nmsu.edu/ molb470/fall2003/Projects/solorz/aliBaba_2_1.htm) and previously published data [21, 22] . We identified three potential NF-κB binding sites. TOV21G and OVCAR8 cells were cultured to approximately 70% confluence before the medium was changed to serum-free medium. Half of the plates were treated with 5 ng/ml of interleukin 1β (IL-1β) for 2 hours. The chromatin immunoprecipitation (ChIP) assay was done as previously described [23] . Briefly, we cross-linked cells using formaldehyde (1%) for 10 minutes at 37°C. The cells were washed and lysed before they were sonicated (Misonix Sonicator 3000; Misonix, Inc, Farmingdale, NY) three times for 10 seconds at maximum output to shear the DNA. DNA fragment size was confirmed at 0.5 to 1.0 kb by electrophoresis. Chromatin DNA was collected by centrifugation and an input sample was collected and stored in −80°C. Supernatant was diluted 1:10 in 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1 and incubated with either 1 μg of p65 antibody or 1 μg of anti-Golgi antibody (58K9; Abcam) and protein A beads overnight at 4°C. The beads were then washed six times in radioimmunoprecipitation buffer (Boston Bioproducts) and two times in Tris-EDTA buffer before the samples were de-cross-linked in 1% SDS, 0.1 M NaHCO 3 at 65°C for 14 hours. De-cross-linked samples were purified using Qiagen's spin columns according to manufacturer's instructions (Qiagen, Valencia, CA). PCR (at 95°C for 5 minutes followed by 35 cycles at 95°C for 30 seconds, at 60°C for 30 seconds, at 72°C for 30 seconds, followed by 72°C for 5 minutes) was performed on (2 μg of total DNA) samples collected before IP(input) as well as after p65-specific and control immunoprecipitation. Primers were designed to span each of the putative NF-κB binding sites as well as two control regions located 2 kb upstream and 2 kb downstream of the Elafin transcription start site. Primer sequences are reported in Table W2 .
Tissue Samples and Immunohistochemistry
After institutional review board approval, sections of formalinfixed, paraffin-embedded (FFPE) human epididymis were obtained from the Department of Pathology at the Brigham and Women's Hospital (Boston, MA) to evaluate the expression of Elafin in this tissue and for subsequent use as positive control tissue. Elafin expression in normal human tissues was analyzed by immunohistochemistry (IHC) as previously described using a collection of normal human tissue blocks [13] , whereas expression in ovarian and non-ovarian tumors was analyzed using high-density tissue microarrays (TMAs) made in-house (see below) or purchased from Biomax US (Rockville, MD). The Elafin affinitypurified rabbit antibody was used at a dilution of 1:1500 with heatinduced epitope retrieval as previously described [13] . Negative controls included protein A-purified preimmune serum, anti-GST antibodies purified as a byproduct of Elafin antibody production, and anti-Elafin antibodies preincubated with recombinant GST-Elafin protein before IHC. None of these controls generated a positive signal in IHC. HE4 localization using affinity-purified antibodies was done as previously described [13] . Slides were counterstained with Mayer hematoxylin.
Primary Tumor Cells
With institutional review board approval, primary ovarian carcinoma cells (DF lines) were isolated directly from peritoneal paracentesis of patients with advanced-stage ovarian cancer at the time of initial cytoreductive surgery. Red blood cells were lysed as previously described [24] , and the samples were enriched for tumor cells either by using immunomagnetic beads coupled to EpCAM antibodies (Dynal/Invitrogen) or by filtration using a 40-μm nylon cell strainer (BD Falcon, San Jose, CA) to isolate tumor cell spheres. Both methods enriched for tumor cells but the yield with the cell strainer was significantly better than with the magnetic EpCAM beads. In all cases, the epithelial nature of the cells was confirmed by EpCAM and HE4 antibody immunostaining as well as reverse transcription-PCR (RT-PCR) detection of CK7. For this study, we used only primary lines that were greater than 80% tumor pure after enrichment.
High-Density TMA
A TMA was constructed from 134 cases of high-grade late-stage ovarian papillary serous carcinoma who underwent primary cytoreductive surgery at Brigham and Women's Hospital. Cases were identified by review of all pathology reports between January 1, 1999, and December 31, 2005 , in the Brigham and Women's Hospital database that included a diagnosis of "ovarian cancer." The rationale for limiting the enrollment date to the year 1999 is that is when taxol became the standard of care, and the cutoff year of 2005 was established to allow adequate follow-up time. All cases that met the eligibility criteria of International Federation of Gynecology and Obstetrics (FIGO) stage III or IV high-grade papillary serous ovarian carcinoma, pathology blocks available for generation of a TMA, and age requirements for one of two cohorts (≤55 years or ≥65 years of age at diagnosis) were included in the TMA (62 cases were from women ≤55 years of age, and 72 cases were from women ≥65 years of age). Patients with known BRCA mutations or with a history of another malignancy (excepting nonmelanoma skin cancers or noninvasive endometrial cancers) in the previous 5 years were excluded. Hematoxylin and eosin slides were reviewed to confirm the original diagnosis and to identify the most appropriate area of tumor for further studies. Corresponding FFPE tissue from each case was used to construct four high-density TMAs: two TMAs containing samples from the younger cohort and two TMAs containing samples from the older cohort. Four cores of tissue were taken from each case, with each core 0.8 mm in diameter. Five-micrometer-thick, unstained sections of the TMAs, as well as 5-μm-thick, unstained "whole mount" sections from the formalin-fixed paraffin-embedded tissue, were used for immunohistochemical analysis, and the findings were correlated with clinical data (age, optimal vs suboptimal cytoreduction status, platinum sensitivity, and overall survival) abstracted from the patient's medical records. Optimal surgical cytoreduction was defined as residual tumor 1 cm or less in diameter, and the duration of overall survival was determined from the date of diagnosis to either death or censored by the date of last follow-up. All pathology specimens and clinical data were collected under the approval of the institutional review board.
Fluorescence In Situ Hybridization
Four-micrometer whole-mount sections of Elafin-positive high-grade papillary serous carcinoma were mounted on standard glass slides and baked at 60°C for at least 2 hours, then deparaffinized and digested using methods described previously [25] . The following DNA fosmid probes were cohybridized: G248P8772D4 and G248P82920B4 (SpectrumGreen), which map to 20q13.12, the latter clone includes the entire coding sequence of PI3/Elafin, and D20Z1 (SpectrumOrange), which maps to 20p11.1-q11.1. The D20Z1 probe was purchased from Abbott Molecular/Vysis, Inc (Des Plaines, IL). Both fosmid probes were obtained from CHORI (www.chori.org), direct-labeled using nick translation and precipitated using standard protocols, and cohybridized as a contig probe. Final (total) fosmid probe concentration was approximately 50 to 100 ng/μl. D20Z1 final probe concentration followed manufacturer's recommendations.
Tissue sections and probes were codenatured, hybridized at least 16 hours at 37°C in a darkened humid chamber, washed in 2× SSC at 70°C for 10 minutes, rinsed in room temperature 2× SSC, and counterstained with 4′,6-diamidino-2-phenylindole (Abbott Molecular/Vysis, Inc). Slides were imaged using an Olympus BX51 fluorescence microscope (Olympus, Center Valley, PA). Individual images were captured using an Applied Imaging system running CytoVision Genus version 3.9 (Applied Imaging, Grand Rapids, MI), and all aberrations detected by fluorescence in situ hybridization (FISH) were reviewed and confirmed by a cytogeneticist (A.L.).
NEMO-Binding Domain (NBD) Assay
Cells were cultured until they reached 60% confluence, after which the medium was changed to FBS-depleted. The cells were incubated with 25 μM NEMO-Binding Domain (NBD) peptide (Calbiochem/ EMD Biosciences, San Diego, CA) or scrambled peptide (Calbiochem/ EMD Biosciences) for 24 hours before the addition of 5 ng/ml of IL-1β. After treatment with IL-1β, the cells were cultured for an additional 2 hours before RNA was harvested, and Elafin expression was monitored by quantitative RT-PCR. Scrambled peptides as well as nontreated cells were used as negative control.
Statistical Analysis
Clinical cases of late-stage ovarian serous carcinoma were scored for Elafin expression according to the following scheme: 0 = no positive cells, +1 = 1% to 5% positive cells, +2 = 6% to 50% positive cells and +3 = more than 50% positive cells (Figure 4 ). Samples were also scored from 1 to 3 depending on the staining intensity. All scoring was blinded and performed by two independent pathologists (R.D. and M.S.H.). The statistical analysis was done by a third party ( J.L.) with no preconception of potential outcome. Before analysis of any survival data, cases were divided into a high-Elafin expressor group (scores of +2 or +3) and a low Elafin expressor group (scores of 0 or +1). KaplanMeier curves were plotted for these two groups to assess overall survival, and the difference between the curves was evaluated using the log-rank test. An estimate of the hazard ratio (HR) was calculated with a Cox proportional hazards model. Statistical analysis was performed using SAS version 9.1 software (SAS, Cary, NC).
Results
Elafin, HE4, and SLPI Constitute a Trio of Overexpressed WAP Genes in Ovarian Cancer
A panel of six ovarian cancer cell lines was screened for expression of WAP genes by RT-PCR. We found three WAP genes, Elafin, HE4, and secretory leukocyte protease inhibitor (SLPI ), variably expressed in the cancer lines. Relative to the IOSE line, HE4 and Elafin were overexpressed only in the cancer lines. Conversely, SLPI was more broadly expressed across all cell lines and IOSE ( Figure 1A ), consistent with our previous observations [13] . Unlike HE4 and SLPI, Elafin expression has not previously been reported in ovarian cancer. We therefore sought to investigate the expression of Elafin in primary tumors. We used Affymetrix U133 Plus 2 chips to compare the gene expression profiles of microdissected late-stage high-grade ovarian serous carcinomas (n = 66) to profiles from microdissected OSE (n = 10). Elafin expression was three-fold higher in the serous late-stage carcinomas, a statistically significant result ( Figure 1B) . Elafin was also significantly overexpressed in early-stage high-grade serous carcinomas (n = 11), low-grade serous carcinomas (n = 18), and high-grade endometrioid carcinomas (n = 18), although there were fewer cases in these cohorts ( Figure 1B) . To confirm the expression profiling results, we conducted quantitative real-time PCR on 20 microdissected late-stage high-grade serous carcinomas and 10 microdissected OSE. Elafin transcript levels were more than 70-fold higher in the serous carcinomas compared with microdissected OSE ( Figure 1C) . We also examined Elafin protein expression in primary human late-stage high-grade serous tumors by IHC and found high levels of expression compared with OSE ( Figure 1D ). The specificity of the Elafin antibody was tested by Western blot analysis ( Figure W1 ) and IHC controls as described in the Materials and Methods. A panel of normal benign human tissues was also examined by IHC for Elafin expression (Table W1) . Interestingly, in the epididymis, an organ devoted to sperm maturation and the native site of WAP gene expression [11, 26, 27] , expression of Elafin was restricted to the p63-and cytokeratin 7-positive basal cells, whereas HE4 expression was restricted to the apical portion of luminal cells (Figure 2 ), suggesting that Elafin may exhibit distinct biologic properties when compared with HE4. 
Analysis of ovarian and non-ovarian cancer cell lines by RT-PCR revealed that Elafin expression is largely restricted to ovarian carcinoma lines, including OVCAR3, OVCAR5, and CaoV3 ( Figure 3A) . Consistent with previous reports [27] , we did not observe Elafin expression in breast cancer cell lines (MCF7 and T47D). In addition, colon (HCT115, HCT116), osteosarcoma (U2OS), kidney (293), lung (Calu-1, NCI-H23), and brain (MO59K) cancer lines failed to express Elafin under these conditions ( Figure 3A and data not shown). Normal diploid fibroblasts (IMR90 cells) were also negative for Elafin expression. The only non-ovarian cancer lines that expressed Elafin in this study were the bladder tumor line T24 and the cervical cancer line HeLa (data not shown). We also analyzed Elafin expression in tumors by hybridizing an Elafin cDNA probe to an ATLAS cancer array membrane (Clontech, Mountain View, CA), which was preloaded with matched RNA from normal/nonneoplastic tissue and tumor tissue derived from the same organ. Our results confirmed the higher expression of Elafin in ovarian tumors (T) versus matched normal (N) tissue ( Figure 3B ). The converse was true for breast normal-tumor pairs. Interestingly, we did observe robust Elafin expression in some nonovarian tumors compared with the matched normal samples, including those from the lung, vulva, and skin, all with squamous histologic diagnosis ( Figure 3B , arrowheads). Expression of Elafin by squamous cell carcinomas was previously reported [29] [30] [31] [32] , and we confirmed it by IHC using Elafin-specific antibodies on a TMA containing multiple tumors, including squamous cell carcinomas from various organ sites ( Figure W2 ).
Elafin contains a signal peptide and is predicted to be a secreted protein [33] . Western blot analysis of conditioned medium from three ovarian cancer lines that express Elafin RNA revealed a secreted form of Elafin that comigrated with the recombinant protein at approximately 12 kDa ( Figure 3C ). In contrast, non-ovarian cancer lines did not secrete Elafin. We also isolated primary tumor cells directly from ascites fluid collected from eighteen patients with advanced serous carcinoma. Samples were enriched for tumor cells as described in the Materials and Methods, and the presence of tumor cells was confirmed by IHC with EpCAM and HE4 antibodies (data not shown). RT-PCR for Elafin showed that approximately half of the primary tumor samples express Elafin, and those that did also secreted Elafin (Figure 3 , D and E; for example compare DF-03, -04, and -20 to DF-09, -22, and -30). As expected, the normal fibroblast line IMR90 was negative for both Elafin and CK7 ( Figure 3D ).
Increased Elafin Expression in Ovarian Carcinomas Correlates with Poor Overall Survival
Our data indicate that Elafin is overexpressed and secreted by ovarian carcinomas. To determine whether Elafin expression is clinically significant, we immunostained an annotated TMA composed of 134 latestage (FIGO stage III and IV) high-grade serous ovarian carcinomas with our rabbit polyclonal antibody against Elafin. Two pathologists (M.S.H. and R.D.) separately scored the sections in a blinded manner according to the grading scale from 0 to 3 ( Figure 4) . Clinical parameters included age, whether optimal cytoreduction had been achieved, platinum sensitivity, and overall survival. Unlike HE4, which tends to show diffuse expression in immunoreactive tumors [13] , Elafin demonstrated a more focal staining pattern, ranging from scattered positive cells and clusters, to larger areas of positivity ( Figure 4A ). To reduce sampling error, whole-mount sections of all the cases were also stained for Elafin ( Figure 4A ). Seventy-seven cases exhibited no (score = 0) or low (score = 1) Elafin expression (n = 33: 0, n = 44: +1) and 57 exhibited high (score = 2 or 3) Elafin expression (n = 45: +2, n = 12: +3). Importantly, there were no statistical differences in the clinical characteristics of the two groups (Table 1) . High Elafin expression in tumor tissue was associated with reduced survival in patients with primary ovarian cancer when the Cox univariate proportional hazards model 
months).
The P value for this difference was .02 by the log-rank test. Elafin remained significantly correlated with overall survival in a multivariate model incorporating age and debulking status ( Table 2) . Of note, although Elafin expression did not correlate with platinum sensitivity or resistance (defined as disease recurrence within 6 months of last receipt of platinum therapy; Table 1 ), 10 of 11 patients with primary platinumrefractory disease (defined as persistent disease or disease progression while receiving platinum-based therapy) had elevated Elafin expression. This correlation was highly statistically significant (P = 8.4 × 10
−6
).
Genomic Gains Drive Elafin Expression in Ovarian Cancers
The correlation between Elafin overexpression and patient outcome prompted us to examine the nature of its overexpression. As described previously, the Elafin gene, PI3, is located on chromosome 20q13.12, a region frequently amplified in ovarian carcinomas [6] [7] [8] . We entertained the possibility that Elafin overexpression might be due to the amplification or gains of its genomic locus and designed DNA fosmid probes for FISH analysis. Whole-mount sections of 10 tumors that were scored +2 or +3 by IHC ( Figure 4A ) were evaluated by FISH for aberrations involving the PI3 genomic locus (green dots). Chromosome 20 centromeric probes (red dots) served as controls for chromosomal copy number. All aberrations were verified by a cytogeneticist (A.H.L.). Copy number changes were classified as amplified when there was a ratio of test probe-control probe (T/C) of 3 or greater. T/C ratios of less than 3 but greater than 1 were interpreted as relative gains of PI3. T/C ratios of 1, even with greater than 2 copies of each probe were classified as polysomy. Although none of the tumors analyzed revealed amplification at the PI3 locus, half of the samples showed gains at this locus relative to the centromeric probe ( Figure 5, A and B) . In addition, trisomy was observed in three of the remaining samples ( Figure 5C ) and disomy in two ( Figure 5D ). These data suggest that in a majority of Elafin-expressing tumors, the underlying mechanism of overexpression may be gains of the PI3 locus and polysomy.
NF-κB Drives Expression of Elafin in Response to Inflammatory Mediators
Although gains at the PI3 locus seem to be common in the tumors we evaluated, it was not the case for all Elafin-expressing tumors and it is likely that other regulatory mechanisms contribute to Elafin expression. Previous studies have demonstrated that Elafin expression is typically induced by inflammation at the transcriptional level; the most striking examples include psoriatic skin and inflammatory airway disease [19, 34] . Given the link between chronic inflammation and ovarian cancer pathogenesis [35] [36] [37] , we examined whether inflammation might contribute to Elafin expression in ovarian cancer. A panel of 13 established ovarian cancer cell lines was screened by RT-PCR. Seven lines were found to strongly express Elafin, whereas six demonstrated minimal or no expression of Elafin ( Figure W3 ). Using both computer algorithms designed to predict transcription factor binding sites in promoter regions and previously published data (reviewed in Chowdhury et al. [22] ), we identified three putative NF-κB transcription factorbinding sites in the promoter region of Elafin ( Figure 6A ). We then treated the ovarian cancer cells that normally express minimal or no Elafin ( Figure W3 ) with the cytokine IL-1β, which is known to induce NF-κB recruitment to promoter elements of responsive genes [38] . Stimulation of HeyA8, OVCAR8, and TOV21G cells with IL-1β for 2 hours resulted in a marked expression of Elafin ( Figure 6B ). Tumor necrosis factor α, another proinflammatory cytokine, had a similar albeit weaker effect (data not shown). Importantly, under the same conditions, IL-1β did not induce the expression of Elafin in a HOSE line ( Figure 6B ). To determine the kinetics of Elafin induction, two cell lines, OVCAR8 and TOV21G, which normally express very low levels of Elafin, were treated with IL-1β, and Elafin expression was monitored over time. Two hours after IL-1β stimulation, a dramatic increase in Elafin expression was detected: 15-fold in OVCAR8 cells ( Figure 6C ) and 5-fold in TOV21G cells (data not shown Figure 6D ), whereas NBD completely blocks the nuclear translocation of p65 in the presence of IL-1β ( Figure 6D ). Under these conditions, cells treated with 25 μM of the NBD inhibitor peptide before stimulation with IL-1β showed no increase in Elafin expression, whereas the scrambled peptide did not inhibit Elafin induction by IL-1β ( Figure 6E ). The effect of NBD was concentration-dependent (data not shown). We further explored the potential direct involvement of NF-κB in the induction of Elafin expression using siRNA to deplete the levels of p65 before IL-1β treatment. Knockdown of p65 was confirmed by Western blot analysis using two different siRNA reagents ( Figure 6F, inset) . OVCAR8 cells treated with control siRNA (GFP) showed comparable levels of Elafin expression to those cells treated with IL-1β only. However, OVCAR8 cells that had been treated with siRNA against p65 showed greatly diminished induction of Elafin in response to IL-1β ( Figure 6F ). This is not likely due to an off-target effect of RNA interference (RNAi) because two different siRNA sequences gave a similar result. Finally, ChIP was used to address whether endogenous p65 occupies its cognate DNA binding sites on the Elafin promoter after cytokine induction, which would suggest that NF-κB directly drives Elafin expression. In both OVCAR8 ( Figure 6G ) and TOV21G cells (data not shown), there was no occupancy of the Elafin promoter by p65 in the absence of IL-1β. However, 2 hours after IL-1β treatment, all three binding sites were occupied ( Figure 6G ). This binding is specific for three reasons: 1) it is only observed in response to a stimulus (IL-1β), 2) control antibodies (α-Golgi) do not precipitate binding activity, and 3) binding is specific to the NF-κB sites because binding was not seen at sequence upstream and downstream of the NF-κB consensus sites ( Figure 6G ). Because the genomic resolution of ChIP is limited by the size of DNA fragments generated (typically 500 bp after sonication), it cannot be concluded that all three NF-κB sites are occupied simultaneously because they all exist within approximately 300 bp of one another ( Figure 6A) . Nonetheless, the results demonstrate that p65 occupancy is dependent on cytokine stimulation. In addition, the overall results strongly argue that induction of Elafin expression by IL-1β is mediated by the NF-κB pathway in ovarian cancer cells that normally do not express the protein. Interestingly, it should be noted that treatment with IL-1β can also induce higher levels of Elafin expression in cell lines that constitutively express Elafin, such as OVCAR3 cells (Figures 6H and W3) . In this setting, knocking down the p65 subunit of NF-κB resulted in a loss of the stimulus-induced expression of Elafin, but there was no effect on the baseline level of expression (data not shown). This latter effect is consistent with our observation that constitutive expression by ovarian tumors is likely mediated by genomic gains of the PI3 locus ( Figure 5 ).
Discussion
In this study, we demonstrate that Elafin is overexpressed and secreted by ovarian carcinomas. To our knowledge, this is the first report linking Elafin to ovarian cancer. We show that Elafin expression is regulated, in part, by gains of the genomic locus and polysomy. We also show that inflammatory mediators can induce expression through the NF-κB pathway, which plays a pivotal role in the link between inflammation and cancer [40] . We could specifically block the induction of Elafin expression with a compound (NBD peptide) that inhibits the proper assembly of the IKK complex necessary for activation of NF-κB. RNAi directed against the p65 DNA binding subunit of NF-κB in the presence or absence of IL-1β demonstrated that knockdown of this subunit abrogated the induction of Elafin expression in response to this inflammatory mediator. Finally, using chromatin immunoprecipitation experiments, we found that NF-κB can specifically occupy cognate binding sites in the Elafin promoter only after stimulation with cytokine. These findings are consistent with previous studies reporting a role for NF-κB in mediating Elafin expression in pulmonary epithelial cells in response to inflammatory mediators [34, 41] .
The role of Elafin in ovarian carcinoma is currently undefined. Elafin is a serine proteinase inhibitor [19] . Its expression, and that of SLPI, is induced under conditions of inflammation and wound healing [42] . Studies on SLPI knockout mice show impaired cutaneous wound healing with increased inflammation and elastase proteinase activity [43] . Whether Elafin plays a similar role is difficult to ascertain because there is no direct homolog of Elafin in mouse [44] . Moreover, although SLPI and Elafin were initially discovered because of their antiproteinase activity, subsequent studies revealed diverse functions including antimicrobial properties and roles in regulating the innate immune system [19] . More recently, several studies showed that overexpression of SLPI is common in certain tumors including pancreatic, uterine, ovarian, and thyroid carcinomas (reviewed in Bouchard et al. [42] ). One study in particular identified SLPI among four genes associated with metastasis and lymph node involvement in breast cancer [45] and another showed that high SLPI expression is associated with decreased diseasefree survival and poor overall survival in breast cancer [46] . The function of SLPI and its antiproteinase activity in this setting are unclear. With regard to Elafin, a connection with cancer is beginning to emerge. A limited body of work shows that Elafin is expressed in a significant number of squamous cell carcinomas [29] [30] [31] [32] , a finding we have confirmed in this study. However, it is unclear whether its expression in these tumors is associated with clinical outcomes. A more recent study identified Elafin expression in glioblastoma multiforme and showed a correlation with poor outcome [47] .
Our analysis of annotated TMAs and corresponding whole-mount tissue sections of ovarian high-grade late-stage serous carcinomas shows that the high expression of Elafin is associated with a poorer overall survival compared with ovarian tumors that express no or low levels of Elafin. Whether Elafin is simply a surrogate for aggressive tumors or it actually functionally contributes to tumor behavior by an as yet undefined mechanism remains to be determined. However, if Elafin secretion leads to its circulation in the bloodstream, it is tempting to speculate that Elafin may serve as a surrogate for more aggressive, possibly more chemoresistant carcinomas that may benefit from alternative therapies. Consistent with this hypothesis, we found that platinumrefractory tumors in our clinical data set were very likely to have elevated levels of Elafin expression, a finding that warrants further investigation.
